Images (1)

Aescin

Authors:Prof. Dr. med. Peter Altmeyer, Prof. Dr. med. Martina Bacharach-Buhles

All authors of this article

Last updated on: 11.09.2023

Dieser Artikel auf Deutsch

Synonym(s)

CAS No.: 6805-41-0; Escin

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Mixture of about 30 esterified triterpene saponins from the seed of horse chestnut(Hippocastani semen, Aesculus hippocastanum, Cortex Hippocastani).

EffectsThis section has been translated automatically.

Low spasmolytic, antiphlogistic, anti-edematous, increase of capillary permeability (slows down the flow of water into the extracapillary space).

Notice! Percutaneous absorption is questionable!

Field of application/useThis section has been translated automatically.

Chronic venous insufficiency, post-thrombotic syndrome, leg ulcers, post-traumatic and postoperative soft tissue swelling, hemorrhoids.

DosageThis section has been translated automatically.

  • Systemic: Inital 3 times 20-40 mg/day, then 2-3 times 20 mg/day p.o.
  • Topical: In general, 1% external agents are used (e.g. 1% aescin gel); apply thinly 3 times/day in the affected area.

Undesirable effectsThis section has been translated automatically.

With systemic use danger of kidney dysfunction up to kidney failure, danger of thrombosis.

With topical application. Allergic skin reactions (contact urticaria) have been described, but are rather rare. Occupational asthmatic reactions caused by workplace conditions containing aescin have been described in isolated cases.

Standard concentrationThis section has been translated automatically.

0.76-2% in ointments, solutions and gels.

ContraindicationThis section has been translated automatically.

Topical appl. Paragroup allergy (ointment), application on mucous membranes or inflamed skin areas and open wounds.

Trade namesThis section has been translated automatically.

Reparil® , Venostasin® , Essaven® Gel, Venoplant® Gel

LiteratureThis section has been translated automatically.

  1. Du Y et al (2016) Combined treatment with low doseprednisone and escin improves the anti-arthritic effect in experimental arthritis. Int Immunopharmacol 31:257-265.

  2. Escribano MM et al. (1997) Contact urticaria due to aescin. Contact dermatitis 37:233.

  3. Luzzi R et al (2011) Aescin: microcirculatory activity. Effects of accessory components on clinical and microcirculatory efficacy. Panminerva Med 53(3 Suppl 1):51-55.

  4. Muñoz X et al,(2006) Occupational asthma related to aescin
    inhalation. Ann Allergy Asthma Immunol 96:494-496.

  5. Vašková J et al (2015) Antioxidant potential of Aesculus hippocastanum extract and escin against reactive oxygen and nitrogen species. Eur Rev Med Pharmacol Sci 19:879-886.

  6. Wang K et al (2015) Escin activates AKT-Nrf2 signaling to protect retinal pigment epithelium cells from oxidative stress. Biochem Biophys Res Commun 468:541-547.
  7. Zhang F et al (2015) Synergistic protective effects of escin and low-dose glucocorticoids against vascular endothelial growth factor-induced blood-retinal barrier breakdown in retinal pigment epithelial and umbilical vein endothelial cells. Mol Med Rep 11:1372-1377.

Authors

Last updated on: 11.09.2023

Authors: Prof. Dr. med. Peter AltmeyerProf. Dr. med. Martina Bacharach-Buhles